Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in advanced bronchiolo-alveolar carcinoma
NCT00118144Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in bronchioloalveolar carcinoma (BAC) and lung adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 5 years. Started Jun 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
bronchioloalveolar carcinoma (BAC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT00118144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118144.